UNSPSC 51292706: Cinanserin hydrochloride

This classification denotes a serotonin antagonist with the molecular formula C20H24N2OS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F65Z32KI62, chemically known as 2-propenamide, n-(2-((3-(dimethylamino)propyl)thio)phenyl)-3-phenyl- but more generally known as cinanserin hydrochloride, which bears US NIH Compound Identifier 5475158. Most nations, for tariff and trade purposes, schedule cinanserin hydrochloride under HS 29309085 and SITC 51549.

As of Q4 2014, CINANSERIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cinanserin hydrochloride bears US NLM identifiers UMLS ID C0242221 and NCI Concept Code C83625. SMILES: CN(C)CCCSC1CCCCC1NC(=O)/C=C/C2CCCCC2.CL.

UNSPSC 51292706 Cinanserin hydrochloride is a Commodity code nominally for a specific pharmaceutical active ingredient, but recent state and local activity shows little procurement aligned to this narrow specification. The source documents three recent opportunities tagged to this code: Seminole County's IFB for naloxone and drug deactivation systems (a public health procurement unrelated to cinanserin), the Texas Health and Human Services Commission's RFI exploring direct-to-manufacturer pharmacy programs, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products. None of these solicitations reference cinanserin hydrochloride or seek this particular active ingredient. The mismatch suggests the code may be misapplied in state and local tagging systems, or the pharmaceutical supply chain uses broader commodity aggregation for procurement purposes rather than ingredient-level coding.

Recent activity spans three jurisdictions — Florida (Seminole County), Texas (state HHS commission), and Minnesota (cooperative purchasing across multiple state and local members) — with no discernible pattern of repeat buyers or concentrated geographic demand under this specific code. Seminole County's naloxone procurement (IFB 60459723LAS, due July 26, 2023) seeks 1,900 units annually with quarterly deliveries. The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) establishes multi-award contracts for generic pharmaceuticals distributed through authorized wholesalers to state and local facilities. The Texas RFI (HHS0017013, posted April 3, 2026) is exploratory market intelligence rather than a formal procurement. The code shows little current relevant activity for cinanserin hydrochloride specifically; vendors should verify actual commodity alignment before investing in pursuit.